When Does Remicade Go Generic?

Remicade is a biologic, so it will not face a traditional "generic." Instead, biosimilar developers file under the FDA's Biologics Price Competition and Innovation Act (BPCIA) pathway and must complete analytical, clinical, and immunogenicity studies to prove no meaningful difference from the reference product. Biosimilar entry is slower and price erosion is gentler than small-molecule generics — discounts of 15–40% are typical rather than the 80%+ collapse seen with pill generics. The BPCIA "patent dance" lets the brand holder assert its portfolio patents serially, which is why a single late-expiring formulation or manufacturing patent (this portfolio runs to 2040) can push real biosimilar availability years past the first composition expiry.

Because Remicade's earliest patent has already expired, generic versions are technically clear to enter the market for that specific patented composition. Whether a generic is actually available depends on FDA Orange Book listings for any later patents, ANDA approvals, and any ongoing Paragraph IV settlements. Patients and prescribers should check the FDA's Orange Book or GoodRx for current generic availability.

When the first Remicade biosimilar launches, expect list-price discounts of roughly 15–40% rather than the steep collapse seen with small-molecule generics. Biosimilars require their own manufacturing and clinical investment, and many payers keep the reference biologic on formulary, so competition builds gradually as additional biosimilars are approved.

The authoritative source for which generic versions are actually approved is the FDA Orange Book, which lists every ANDA-approved equivalent and the patents an applicant had to clear. To compare cash prices once a generic lands, check GoodRx and Mark Cuban's Cost Plus Drugs. Underlying patent expiration data on this page is sourced from USPTO PatentsView.

Remicade is protected by 12 US patents, a mid-sized portfolio that is typical for an established branded drug in mid-lifecycle. The portfolio likely combines a primary composition-of-matter patent (the strongest form of protection) with a layer of formulation, dosing, and method-of-use patents that extend exclusivity beyond the original composition expiry — a common strategy known as "patent layering" or, less charitably, "evergreening."

All 12 patents in the Remicade portfolio are assigned to Janssen Biotech Inc., indicating consolidated ownership. Single-assignee portfolios are simpler to litigate and easier to license — generic challengers face one negotiating counterparty, and any settlement or pay-for-delay arrangement involves only that holder.

The Remicade portfolio scores 61/100 (Grade C, "moderate") on the PatentCliff Strength index. The strongest signal is portfolio size (92/100), and the weakest is technology diversity (37/100). The four factors are weighted by how well they predict real-world resilience to generic challenge: portfolio size 30%, claims breadth 25%, time remaining 25%, and technology diversity 20%.

Looking at the 12 dated patents in the portfolio, the largest cluster (5 patents) falls in the "2–5 years (2029–2031)" bucket. That distribution matters because generic entry is gated by the latest unexpired blocking patent, not the earliest — even one late-expiring formulation patent can delay biosimilar launch by years if it survives a Paragraph IV challenge.

The 20-year patent term in the United States runs from the earliest non-provisional filing date, not the grant date. That means a patent granted in 2015 from a 2010 filing has only 15 years of life left at grant — a feature of US patent law that creates the layered "cliff" pattern visible in most branded drug portfolios. Patent Term Extension under 35 USC § 156 can add up to 5 years for time lost to FDA review, and pediatric exclusivity can add 6 months on top.